SNC-102
Phase 2Small molecule
SNC-102 is one of 41 small molecule programs targeting Tourette syndrome. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
40
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Tourette Syndrome
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Marinol
Alnylam PharmaceuticalsApproved
Rilutek
AAzurity Pharmaceuticals
Approved
Abilify
OtsukaApproved
Bendopa
MMerz Pharmaceuticals GmbH
Approved
Haldol
DDePuy Orthopaedics
Approved
Strattera
MMap77
Approved
Intuniv
PPromius Pharma, LLC
Approved
Topamax
WWim Janssens
Phase 3
Mirapex
Boehringer IngelheimPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SNC-102. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSynchroneuron Inc.